Alamar Biosciences, Inc.
- ALMR ยท Nasdaq
- Laboratory Analytical Instruments
- Fremont, CA
- CIK 0002104204
Updated from SEC filings through
Top things to know
Executives
- Yuling Luo PhD, founder, CEO, and chair of Alamar Biosciences 8-K, 2026-11-03
- Justin J. McAnear Chief Financial Officer 4, 2026-04-20
- Shiping Chen Chief Operating Officer 4, 2026-04-20
- Timothy Ogden White President 4, 2026-04-20
- John L. Brottem General Counsel 4, 2026-09-16
What leadership is saying
“Our third quarter results reflect continued strong demand for our platform, with revenue up 68% and biopharma customers accounting for the largest portion of our revenue for the first time”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
Alamar Biosciences, Inc. is a U.S. public company in laboratory analytical instruments (SIC 3826), headquartered in Fremont, CA. It trades as ALMR on Nasdaq. Yuling Luo is PhD, founder, CEO, and chair of Alamar Biosciences.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Yuling Luo Founder, Chairman & CEO, at Alamar Biosciences | PhD, founder, CEO, and chair of Alamar Biosciences | 8-K, 2026-11-03 |
| Justin J. McAnear | Chief Financial Officer | 4, 2026-04-20 |
| Shiping Chen | Chief Operating Officer | 4, 2026-04-20 |
| Timothy Ogden White | President | 4, 2026-04-20 |
| John L. Brottem General Counsel at Alamar Biosciences, Inc. | General Counsel | 4, 2026-09-16 |
What Alamar Biosciences, Inc. does
We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.
Shares and governance
| Shares outstanding | 69.5 million (as of October 31, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| April 20, 2026 | Nicholas Naclerio Director | Buy | 235,294 | $4.0M | Form 4, April 20, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-01
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-15
- Item 8.01 Other events
- 8-K filed 2026-05-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-20
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
Frequently asked questions about Alamar Biosciences, Inc.
- What does Alamar Biosciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation."
- Who is the CEO of Alamar Biosciences, Inc.?
- Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences, as named in a 8-K filed November 3, 2026.
- Who is the CFO of Alamar Biosciences, Inc.?
- Justin J. McAnear, Chief Financial Officer, as named in a 4 filed April 20, 2026.
- Where is Alamar Biosciences, Inc. headquartered?
- Fremont, CA.
- What is Alamar Biosciences, Inc.'s stock ticker?
- ALMR on Nasdaq.
- What industry is Alamar Biosciences, Inc. in?
- Laboratory Analytical Instruments, SIC code 3826.
- What is Alamar Biosciences, Inc.'s website?
- alamarbio.com. Investor relations: https://alamarbio.com/company/investors/.
- When does Alamar Biosciences, Inc. report earnings next?
- November 9, 2026. Source: pg_earnings_events.
- Is Alamar Biosciences, Inc. a public company?
- Yes. Alamar Biosciences, Inc. files with the SEC under CIK 0002104204 and trades as ALMR.
- How many shares of Alamar Biosciences, Inc. are outstanding?
- 69.5 million shares as of October 31, 2026, from its 10-Q filed November 4, 2026.
- How many business segments does Alamar Biosciences, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- Have Alamar Biosciences, Inc. insiders traded stock recently?
- Since April 20, 2026, officers and directors reported 0 open-market sales and 1 purchase worth about $4.0M on Forms 4 and 5. The most recent: Nicholas Naclerio (Director) bought 235,294 shares on April 20, 2026.